Vanguard Group’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$104M Buy
15,470,365
+275,802
+2% +$2.08M ﹤0.01% 1859
2025
Q3
$132M Sell
15,194,563
-238,649
-2% -$1.86M ﹤0.01% 1735
2025
Q2
$97.2M Sell
15,433,212
-241,166
-2% -$1.6M ﹤0.01% 1841
2025
Q1
$100M Sell
15,674,378
-51,872
-0.3% -$429K ﹤0.01% 1791
2024
Q4
$126M Buy
15,726,250
+296,181
+2% +$2.86M ﹤0.01% 1763
2024
Q3
$195M Buy
15,430,069
+1,354,696
+10% +$17.5M ﹤0.01% 1556
2024
Q2
$178M Buy
14,075,373
+582,099
+4% +$5.86M ﹤0.01% 1551
2024
Q1
$64.5M Sell
13,493,274
-1,066,787
-7% -$4.95M ﹤0.01% 2062
2023
Q4
$69.9M Buy
14,560,061
+3,008,585
+26% +$18.4M ﹤0.01% 2040
2023
Q3
$83.6M Buy
11,551,476
+978,873
+9% +$7.82M ﹤0.01% 1900
2023
Q2
$78.6M Buy
10,572,603
+378,645
+4% +$2.98M ﹤0.01% 1984
2023
Q1
$70.6M Buy
10,193,958
+1,349,305
+15% +$12.4M ﹤0.01% 2010
2022
Q4
$90.9M Buy
8,844,653
+1,348,729
+18% +$23.8M ﹤0.01% 1852
2022
Q3
$136M Buy
7,495,924
+144,999
+2% +$6.28M ﹤0.01% 1613
2022
Q2
$378M Buy
7,350,925
+383,982
+6% +$19.9M 0.01% 1026
2022
Q1
$513M Buy
6,966,943
+69,936
+1% +$6.24M 0.01% 942
2021
Q4
$987M Buy
6,897,007
+100,009
+1% +$17.2M 0.02% 663
2021
Q3
$1.41B Buy
6,796,998
+126,338
+2% +$27.8M 0.04% 522
2021
Q2
$1.42B Buy
6,670,660
+777,356
+13% +$142M 0.04% 527
2021
Q1
$1.07B Buy
5,893,304
+294,544
+5% +$58.7M 0.03% 601
2020
Q4
$624M Buy
5,598,760
+167,200
+3% +$17.8M 0.02% 772
2020
Q3
$589M Buy
5,431,560
+793,923
+17% +$96.7M 0.02% 705
2020
Q2
$387M Buy
4,637,637
+2,579,671
+125% +$98.7M 0.01% 883
2020
Q1
$27.9M Buy
2,057,966
+576,107
+39% +$4.87M ﹤0.01% 2137
2019
Q4
$5.9M Sell
1,481,859
-64,975
-4% -$282K ﹤0.01% 3117
2019
Q3
$7.76M Buy
1,546,834
+146,168
+10% +$800K ﹤0.01% 2950
2019
Q2
$8.21M Buy
1,400,666
+90,603
+7% +$713K ﹤0.01% 2972
2019
Q1
$14.4M Buy
1,310,063
+251,623
+24% +$7.94M ﹤0.01% 2652
2018
Q4
$39M Sell
1,058,440
-58,133
-5% -$2.25M ﹤0.01% 2148
2018
Q3
$42M Buy
1,116,573
+64,582
+6% +$1.82M ﹤0.01% 2232
2018
Q2
$28.2M Buy
1,051,991
+248,412
+31% +$8.4M ﹤0.01% 2412
2018
Q1
$33.8M Buy
803,579
+84,236
+12% +$3.38M ﹤0.01% 2271
2017
Q4
$17.8M Buy
719,343
+77,857
+12% +$1.9M ﹤0.01% 2532
2017
Q3
$14.6M Sell
641,486
-228,319
-26% -$5.11M ﹤0.01% 2636
2017
Q2
$20M Sell
869,805
-214,261
-20% -$4.2M ﹤0.01% 2458
2017
Q1
$27.8M Buy
1,084,066
+46,929
+5% +$1.29M ﹤0.01% 2296
2016
Q4
$26.1M Buy
1,037,137
+26,346
+3% +$768K ﹤0.01% 2300
2016
Q3
$42M Buy
1,010,791
+14,040
+1% +$1.81M ﹤0.01% 2009
2016
Q2
$145M Buy
996,751
+69,282
+7% +$7.94M 0.01% 1249
2016
Q1
$95.7M Buy
927,469
+26,578
+3% +$2.85M 0.01% 1513
2015
Q4
$151M Buy
900,891
+19,286
+2% +$2.97M 0.01% 1175
2015
Q3
$125M Buy
881,605
+68,263
+8% +$15.3M 0.01% 1289
2015
Q2
$181M Buy
813,342
+193,700
+31% +$34M 0.01% 1115
2015
Q1
$102M Buy
619,642
+251,862
+68% +$40.9M 0.01% 1481
2014
Q4
$43.6M Buy
367,780
+13,679
+4% +$1.43M ﹤0.01% 1899
2014
Q3
$29.5M Buy
354,101
+12,532
+4% +$1.13M ﹤0.01% 2057
2014
Q2
$31.6M Buy
341,569
+44,466
+15% +$3.91M ﹤0.01% 2055
2014
Q1
$26.9M Buy
297,103
+22,911
+8% +$2.56M ﹤0.01% 2092
2013
Q4
$28.1M Buy
274,192
+60,126
+28% +$4.25M ﹤0.01% 2044
2013
Q3
$13.5M Buy
214,066
+30,942
+17% +$1.74M ﹤0.01% 2257
2013
Q2
$7.51M Buy
+183,124
New +$7.93M ﹤0.01% 2462

Other funds holding NVAX

Vanguard Group's NVAX Position: Q4 2025 in Review

Vanguard Group increased its Novavax (NVAX) stake by 1.8% in Q4 2025, buying an estimated $2.08M and bringing the position to 15,470,365 shares worth $104M. The position accounts for ﹤0.01% of the portfolio, ranked #1859.

Vanguard Group first reported a position in NVAX in Q2 2013 and has held it in 51 quarters since. The position peaked at $1.42B in Q2 2021. 234 funds tracked by Wall St. Rank hold NVAX as of Q4 2025.

  • Vanguard Group held 15,470,365 shares of Novavax worth $104M as of Q4 2025.
  • Vanguard Group bought 275,802 Novavax shares in Q4 2025, an estimated $2.08M.
  • Novavax made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1859 holding.
  • Vanguard Group first reported a position in Novavax in Q2 2013 and has held it in 51 quarters since.
  • Vanguard Group's Novavax position peaked at $1.42B in Q2 2021.
  • 234 funds tracked by Wall St. Rank held Novavax as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.